Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.01.2015 | main topic | Ausgabe 1-2/2015

Wiener Medizinische Wochenschrift 1-2/2015

Biological agents in psoriatic arthritis

Wiener Medizinische Wochenschrift > Ausgabe 1-2/2015
MD Roland Kocijan, MD Christian Muschitz, MD Jürgen Rech


Anti-tumor necrosis factors (TNFs) are effective drugs for the treatment of psoriatic arthritis (PsA) regarding reduction of pain and inflammation, enthesitis, dactylitis, as well as psoriatic skin and nail disease. Moreover, radiographic progression in PsA is decelerated. The efficacy of anti-TNFs seems to be independent of synthetic disease-modifying anti-rheumatic drugs, suggesting only a minor role of combination therapy in PsA. Anti-TNFs are generally well tolerated in patients with PsA. Adverse events are similar to those reported in patients with rheumatoid arthritis. Ustekinumab, a recently approved IL-12/IL-23-antibody is another promising biological agent in the treatment of PsA.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Über diesen Artikel

Weitere Artikel der Ausgabe 1-2/2015

Wiener Medizinische Wochenschrift 1-2/2015 Zur Ausgabe


Biologika bei SLE